Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 1/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CRHBP | P24387 | 1/20 | 0.59 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1223595 | 1.00 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL1223594 | 1.00 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL14107329 | 0.89 | TRPM5 (0.81) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL12881201 | 0.89 | TRPM5 (0.81) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL3974398 | 0.89 | TRPM5 (0.80) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL14417616 | 0.89 | TRPM5 (0.80) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL1225195 | 0.86 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL2782478 | 0.86 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL1225192 | 0.86 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA | |
| SCHEMBL1225191 | 0.86 | TRPM5 (1.00) | TRPM5KDM4EMAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| EP-2107908-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | Redpoint Bio Corporation (US) | 2009-10-14 | — | — | EP | claimed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | claimed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | claimed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2107908-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | Redpoint Bio Corporation (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1951215-A4 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1951215-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | Redpoint Bio Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | TRPM5 49/4885KDM4E 3193/4885MAPT 4421/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | TRPM5 3/4885KDM4E 2793/4885MAPT 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.